Q3 2024 Liquidia Corp Earnings Call Transcript

Nov 13, 2024 / 01:30 PM GMT

Release Date Price: €9.87 (-0.90%)

Transcript 10-Q8-K

Key Points

Positve

Liquidia Corp (LQDA) has a clear path to seeking final approval for Reia, with potential approval as early as May 2025.
The company has successfully expanded its relationship with Hermosa, securing rights for L 606 in the EU and other territories outside North America.
Liquidia Corp (LQDA) has strengthened its balance sheet with approximately $100 million raised through several financing transactions.
The clinical progress of Reia and L 606 is promising, with positive preliminary data from the Ascent study showing good tolerability and titratability.
The company has a well-prepared sales force with significant experience in rare diseases, ready to launch Reia upon FDA approval.

Negative

The final approval of Reia is currently delayed due to the FDA's decision to grant exclusivity to a competitor, which Liquidia is challenging in court.
Research and development expenses have increased significantly, up 60% from the previous year, impacting the company's financials.
General and administrative expenses have nearly doubled, primarily due to increased personnel and legal fees.
The company faces ongoing litigation challenges, including a lawsuit against the FDA and a patent dispute with United Therapeutics.
The timeline for the L 606 pivotal study has been pushed to the first half of 2025 due to the integration of a new nebulizer device.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

LQDA.OQ - Liquidia Corp
Q3 2024 Liquidia Corp Earnings Call
Nov 13, 2024 / 01:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning and welcome everyone to Liquidia Corporation third quarter, 2024 financial results and corporate update conference call. My name is Michelle and I will be your conference operator today.

Currently, all participants are in a listen-only mode. Following the presentation, we will conduct a question and answer session. Instructions will be provided at that time for you to queue up for questions. I would like to remind everyone that this conference call is being recorded. I would now like to hand the conference over to Jason Adair, Chief Business Officer. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
-------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.